Please enable JavaScript.
Coggle requires JavaScript to display documents.
Lixisenatide Incretin Mimetics (Side effects (Trouble swallowing,…
Lixisenatide
Incretin Mimetics
Mechanism of action
Lixisenatide is a GLP-1 receptor agonist that works by increasing glucose-dependent insulin release, decreasing glucagon secretion, and slowing gastric emptying.
Insulin glargine works through regulation of glucose metabolism. Specifically, insulin lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production.
Contraindications
Alcoholism, cholelithiasis, pancreatitis
Diabetes ketoacidosis, type1 diabetes mellitus
Angiodema, hypersensitivity or anaphylaxis
Hypoglycemia
Pregnancy
Children
Route
Subcutaneous route
Storage
Both products should be stored in the refrigerator prior to first use. Subsequently, they are recommended to be kept at room temperature. Each pen should be discarded 14 days after first use.
Indications
Both Adlyxin and Soliqua 100/33 are FDA-approved as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Soliqua 100/33 is indicated specifically in those inadequately controlled on basal insulin (less than 60 units daily) or lixisenatide.
Nursing considerations
No dosage adjustment needed. Monitor closely for adverse reactions, especially hypoglycemia, nausea, and vomiting, and for changes in renal function.
Dehydration and acute renal failure and worsening of chronic renal failure may occur in these patients.
Clinical experience is limited; lixisenatide exposure is higher in these patients. Monitor closely for adverse reactions, especially hypoglycemia, nausea, and vomiting, and for changes in renal function. Dehydration and acute renal failure and worsening of chronic renal failure may occur in these patients.
Side effects
Trouble swallowing
Difficult breathing
Rapid heartbeats
Feeling light headed
Itching severe rash
Seelling of your face, lips, tounge
Hives
Swelling of throat